Bupivacaine low dose — Competitive Intelligence Brief

Bupivacaine low dose (Bupivacaine low dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesia/Pain Management.

marketed Local anesthetic Voltage-gated sodium channels Anesthesia/Pain Management Small molecule

Target snapshot

Bupivacaine low dose (Bupivacaine low dose) — Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias. Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bupivacaine low dose TARGET	Bupivacaine low dose	Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias	marketed	Local anesthetic	Voltage-gated sodium channels
Lidocaine/Magnesium	Lidocaine/Magnesium	University of Wisconsin, Madison	marketed	Local anesthetic combination	Voltage-gated sodium channels; NMDA receptor
Bupivacaine + nalbuphine	Bupivacaine + nalbuphine	Alzahraa Ahmed Abbas	marketed	Local anesthetic + mixed opioid agonist-antagonist	Voltage-gated sodium channels (bupivacaine); kappa and mu opioid receptors (nalbuphine)
Lidocaine aerosol 2.4% topical	Lidocaine aerosol 2.4% topical	Jiangang Song	marketed	Local anesthetic	Voltage-gated sodium channels
bucain + fentanyl	bucain + fentanyl	University of Debrecen	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (bucain); mu-opioid receptor (fentanyl)
Anesthesia (Lidocaine 15%)	Anesthesia (Lidocaine 15%)	Lumbini Medical College	marketed	Local anesthetic	Voltage-gated sodium channels
Ropivacaine + Midazolam	Ropivacaine + Midazolam	Aga Khan University	marketed	Local anesthetic + benzodiazepine combination	Voltage-gated sodium channels (ropivacaine); GABA-A receptors (midazolam)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class